When frostbitten limbs warm up again, blood rushes back into the tissue. With that blood come compounds such as histamines ...

New data suggests clinicians may be slower to recognize sepsis in people with pulmonary arterial hypertension.

Winrevair lowered death or transplant risk in adults with PAH functional class 3-4 at high risk of dying; all in study may ...

The study was stopped early to allow all patients with advanced PAH the option for treatment with the activin signaling ...

An independent data monitoring committee has recommended terminating the ZENITH study early based on the results.

The company plans to use the proceeds to advance its pipeline of Activin and GDF inhibitors, HS135 for pulmonary hypertension and HS235 for cardiometabolic disease and obesity. The Series C financing ...

In recent health developments, the FDA approved a new drug by BridgeBio for a deadly heart condition. Additionally, Merck's ...

Heart failure with preserved ejection fraction (HFpEF) is underdiagnosed in patients with severe secondary tricuspid ...

The preliminary data open the door to an alternative approach to invasive monitoring in heart failure patients.

Participants were randomly assigned to receive subcutaneous sotatercept or placebo every 21 days with background PAH therapy. The primary endpoint was the time to first confirmed morbidity or ...

Positive study results for Winrevair could help the drugmaker achieve sales growth past top-seller Keytruda’s upcoming patent ...

Merck Announces Pivotal Phase 3 ZENITH Trial Evaluating WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint at Interim ...